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The accompanying editorial, headed 
“A victory in the battle against hunger”, 
said the news was “a cause for major 
congratulation” to the scientists 
involved, and for the decision to place 
their findings openly on the internet.
Now here are some readers’ 
responses: “I will never eat the crap. 
Are you out of your mind?”, “Sounds 
like ‘cure for cancer has been found’. 
Big corps would not allow their markets 
demise, just like the ‘cancer industry’!”, 
“GMO is a potential new plague 
brought about by mankind’s greedy 
behaviour – birth control and reforms 
are the solution to overpopulation, 
not GMO. The EU should ban GMO 
forthwith”, “The words ‘Play with the 
natural balance of nature at your peril’ 
come to mind. It seems akin to taking 
a buzzsaw to a finely tuned ecosystem. 
Taking random cuts through the chain 
of life that binds us all”, “I am NOT for 
GMO foods because of the KNOWN 
mutations they cause to the HUMAN 
genome”, “And there they sit, the Uber-
Rich patent holders, their backyards 
filled with totally resilient wheat, while 
the rest of the world, without the means 
to afford it, or even the means to save 
themselves from starvation, will die in 
the swamps of Mother Nature’s own 
selective breeding program.”
Even in the USA, which never 
experienced the European anti-GM 
furore, press coverage was followed 
by angry ripostes. “Scientists have 
published the first genome of wheat, 
an achievement that should benefit 
food security challenged by the Earth’s 
population, climate change and 
emerging plant pasts,” the Discovery 
channel announced.
“Scientists are too stupid to see the 
WHOLE picture of what this will do,” 
said one response, “It will only cause 
more intolerances, more digestive 
issues, more toxin accumulation in 
bowels (because the proteins which 
were easy to break down are now 
more ‘resilient’ to everything).” “Kiss 
wheat as we know it goodbye… Just 
like Monsanto Corp. There is no more 
natural soya,” said another. “I love 
science, but it’s supposed to help us 
understand nature, not change it.”
Misapprehensions maybe. Atypical 
perhaps. But the vox pop now available 
through the Internet on occasions of 
this sort provides sobering insights for 
scientists everywhere.
Bernard Dixon is the European editor of the 
American Society for Microbiology.
In the final years of the last century, 
the human genome project and Craig 
Venter’s competing private sequencing 
effort raised hopes and fears that 
now, with hindsight, appear naïve. 
There were hopes for immediate 
medical benefits from identifying the 
genetic variations that cause common 
diseases, and there were fears that 
the ability to read the human genome 
would make humans ‘transparent’ in 
that their traits and indeed their fate 
could be predicted from the genome, 
an idea that has been explored in the 
movie ‘GATTACA’ (1997).
Ten years on, we have come to 
realise that this promised revolution is 
more complex, as the human genome 
has yielded no simple explanations for 
common medical conditions. In the 
meantime, however, sequencing 
capacity, speed and affordability 
have improved rapidly, such that 
many ‘personal’ genomes of specific 
individuals, can now be analysed, 
and even ancient genomes like that 
of Homo neanderthalensis have 
become accessible. The multitude of 
individual genomes, ideally connected 
to information about the phenotype 
of the genome carrier, is exactly what 
researchers need in order to make 
medical sense of the genome, after 
realising that the answers are a lot more 
complicated than most people thought. 
With personal genomics and 
genome-wide association studies, the 
hopes and fears of the millennium are 
returning in a new guise. Initiatives 
like the 1000 genomes project aim at 
making genomic information widely 
available, so it can be analysed by 
many researchers in different ways. 
Informed consent of the study 
participants is deemed sufficient to 
ward off unwanted side-effects. 
On the other hand, not all study 
participants are sufficiently educated 
to be able to give their informed 
consent to a genomic study, and even 
the most knowledgeable participants 
cannot look into the future and work 
out what may happen to their genome 
data after they enter the public domain. 
In the absence of political guidance 
in a field that moves much faster 
than legislation, bioethics experts 
in academia are attempting to set 
guidelines for good practice. This 
month, they held the first major 
international meeting on data 
sharing at St. Hugh’s College, 
Oxford. Adopting an innovative open 
discussion format, the conference 
addressed questions such as: 
•   How should data-generators be 
rewarded for their efforts to the 
scientific community?
The extent to which datasets are 
openly shared raises privacy fears. 
Michael Gross reports.
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Analysis: Genetic studies on human tissues are increasingly raising questions about data 
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•   Can scientists promise anonymity 
of research participants when 
whole sequences data and 
phenotypic data are being used 
for research purposes?
•   Should participants be fed back 
individual findings?
•   Are national research governance 
systems adequate to cope with 
global data sharing?
•   What innovative IT solutions can be 
brought into this field to address 
these challenges and further 
promote data sharing?
Oxford academic Jane Kaye, 
who organised the conference 
and chairs the Centre for Health, 
Law, and Emerging Technologies 
(HeLEX), is working towards a ‘good 
practice’ guide for the sensitive fields 
surrounding genomics, biobanks, and 
data sharing, reconciling the interests 
of researchers and study participants, 
without unduly hindering research. 
Bioethicists working closely 
with a research project known as 
MalariaGEN (Malaria Genomic 
Epidemiology Network) have 
already developed procedures for 
the controlled access to genomic 
data in studies involving vulnerable 
participants, where the notion 
of informed consent is proving 
problematic. 
As malaria mainly affects sub-
Saharan Africa, genomic studies of 
malaria susceptibility necessarily involve 
DNA samples from individuals with 
limited experience or understanding of 
medical research, who might be unable 
to comprehend what might happen with 
their genetic information once it became 
publicly accessible. 
“Because we are aware of the limits 
of consent in such cases, we have 
decided not to release data without 
regulation,” explains Jantina de Vries, 
one of the bioethicists involved in the 
project. In close consultation between 
researchers, ethics committees, 
funding bodies and others, MalariaGEN 
set up a dedicated review panel to 
control access to the genomic data 
generated by the project, the IDAC 
(Independent Data Access Committee). 
The six members of IDAC, all experts in 
relevant disciplines, review all requests 
for access to MalariaGEN data. An 
application form for people interested in 
the data is to be found online, and they 
will have to justify their request with a 
description of their research interest, 
typically about a paragraph or two long. 
MalariaGEN’s data release policy 
also includes the option of delaying 
access for nine months after the date 
when the researchers who created 
the data first had access to it, in order 
to protect the emerging capacity of 
African researchers. 
Some other researchers and 
institutions appear to think that this 
much protection is unnecessary. “This 
area is currently open to debate,” 
admits de Vries. There are many 
prominent genomics researchers 
and research funders who argue 
that unrestricted open access to 
genomic data — with consent 
taken to imply that the DNA donors 
understand the full implications of 
their participation — is the best way 
to promote scientific progress in the 
pursuit of better understanding of 
serious diseases. The bioethicists 
working with MalariaGEN however 
believe that a managed approach to 
data-release is a more sustainable and 
appropriate approach to the promotion 
of science in a global context. 
“We see our approach as a 
contribution to the debate,” says 
de Vries. “It shows that such research 
can be done in an ethical way.” 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web page 
at www.michaelgross.co.uk
A genetically modified salmon is under 
consideration by the US Food and 
Drugs Administration (FDA) which 
could sanction the first such modified 
animal for human consumption. They 
announced earlier this month an 
analysis which found the fish safe to eat 
and unlikely to harm the environment.
Atlantic salmon usually do not grow 
in the winter and take three years to 
mature. Aqua Bounty Technologies 
of Waltham, Massachusetts, has 
invested more than 14 years and 
$60 million developing and seeking 
approval of its AquAdvantage salmon, 
which incorporates genetic material 
from a Chinook salmon and a pout 
fish. The company says its fish look 
and taste like non-engineered North 
Atlantic salmon, consume up to 25 
per cent less food and reach market 
weight in half the time.
require that the fish are raised 
on farms inland. But critics are 
concerned. Andrew Good of 
the Atlantic Salmon Federation 
says he wants a thorough risk 
assessment of the GM salmon  
to be conducted to protect wild 
salmon.
A new genetically modified salmon is 
under consideration in the US.  
Nigel Williams reports.
GM salmon loom If the FDA’s Center for Veterinary Medicine approve the fish, Aqua 
Bounty Technologies believe it could 
be in commercial production within a 
year, and available to purchase within 
two years. 
To reduce the risk to the 
environment, any approval will 
Speeding up: A new genetically modified version of the Atlantic salmon here is claimed to 
reach market weight in half the time of conventional fish. (Picture: Photolibrary.)
